Skip to main content

01.12.2018 | Case report | Ausgabe 1/2018 Open Access

BMC Gastroenterology 1/2018

Case report on pathogenetic link between gluten and IgA nephropathy

BMC Gastroenterology > Ausgabe 1/2018
Stefano Costa, Giovanni Currò, Salvatore Pellegrino, Maria Cristina Lucanto, Giovanni Tuccari, Antonio Ieni, Giuseppina Visalli, Giuseppe Magazzù, Domenico Santoro
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12876-018-0792-0) contains supplementary material, which is available to authorized users.
Celiac disease
Cystic fibrosis
Dermatitis herpetiformis
Gluten ataxia
IgA nephropathy
IgA-tissue antitransglutaminase antibodies


A relationship between celiac disease and other autoimmune inflammatory disorders is known [ 1]. With regardto IgA nephropathy (IgAN), some studies report an increased incidence of celiac disease [ 2] and postulate a role of gluten in the pathogenesis of this disorder [ 3, 4]. A double immunofluorescence technique to detect intestinal deposits of anti-tissue transglutaminase IgA was successfully performed in patients with dermatitis herpetiformis (DH) [ 5] and gluten ataxia (GA) [ 6] showing a link between gluten and these diseases even in absence of duodenal atrophy or positive celiac serology.
We used this technique to detect anti-TG2 in the mesangium and duodenum of a patient with IgAN.

Case presentation

A 39-year-old man with CF and CF-related diabetes came to our Unit due to symptoms of pulmonary exacerbation. At the same time, he started to present gross hematuria, back pain and headache. At admission, laboratory analysis showed increase in serum creatinine of 1.5 mg/dl together with hematuria and mild proteinuria (1 g/24 h). Intravenous antibiotics for pulmonary exacerbation (piperacillin/tazobacatam and colimycin) were started and a renal biopsy performed to investigate the cause of hematuria and renal failure. Biopsy was consistent with IgAN (see Fig.  1d), with morphological features of mesangial and endocapillary hypercellularity (Oxford classification M1, E1, S0, T0) [ 7] As the patient presented dyspepsia, he was offered upper gastrointestinal endoscopy with duodenal biopsies (one from duodenal bulb and three from descending duodenum). Duodenal mucosa was reported as normal on hematoxylin/eosin stain. While compatible HLA alleles for celiac disease (DQ2) were identified, both serum anti-endomysium (EMA) and anti-tissue transglutaminase antibodies (anti-tTG) were negative. It has been demonstrated that coeliac IgA targets intestinal TG2 early in disease development even when serum celiac autoantibodies are not present. Extraintestinal deposits of coeliac IgA further indicate that humoral immunity may have a pathogenetic role [ 8]. Therefore, double immunofluorescence on duodenal mucosa was performed to detect mucosal deposits of anti-tissue transglutaminase type 2 using the technique described by Karponay-Szabo et al., with some modification [ 8]. Briefly, 5 μm sections from the duodenal specimen included in optimal cutting temperature (OCT) compound were obtained and stored at − 80° in liquid nitrogen. Sections were fixed in acetone and incubated with Normal Rabbit Serum (Calbiochem Germany) for 20 min to block nonspecific sites. Sections were then incubated with anti-tissue transglutaminase type 2 (anti-tTG-2) from mouse (CUB7402 from Neomarker, Fremont CA) for one hour, and then with secondary antibodies conjugated with fluorochromes to detect total IgA (in green using Polyclonal Rabbit anti-Human IgA/FICT from Dako, Denmark) and anti-tTG-2 (in red using Polyconal Rabbit anti-Mouse RPE F (ab’) 2 from Dako, Denmark) for 30 min. The overlap of green and red (yellow) indicates the deposits of anti-tTG2. Analysis was performed on confocal microscopy. The same technique was performed on 5 μm renal sections. In both cases, an overlap of green and red in yellow was seen, thus demonstrating deposits of tTG-2 (Fig.  2a, b and c). In particular, in renal biopsies, deposits of tTG-2 that topographically replicated mesangial deposits of IgA (Fig.  1) were detected.
Given the morphological features of IgAN, and the presence of proteinuria, steroid therapy was started according to a standardized six month’s protocol [ 9]. After one month, proteinuria decreased to 100 mg/24 h and hematuria resolved. Steroids were stopped after six months of treatment. The patient continued on a gluten containing diet.
Considering that intestinal deposits of anti-tissue transglutaminase IgA are predictive of forthcoming enteropathy [ 10] after one year arepeat upper endoscopy was performed even though anti-tTG were still negative. At this time, a Marsh 2 type duodenal pathology was detected (Fig.  3a, b). A gluten free diet was started (for a complete timeline history see Additional file 1: Table S1).

Discussion and conclusions

To our knowledge, this is the first demonstration of the pathogenetic role of gluten in IgAN. IgAN is a rare complication of CF [ 11]. In these cases, it is supposed that aninfectious stimulus acts as a trigger. On the other hand, a relationship between CD and IgAN has previously been suggested. In 2002, Collin et al. demonstrated an incidence of 3.6% of biopsy proven CD in IgAN [ 2]. On the other hand, a recent study demonstrated an increased risk of biopsy-verified IgAN among individuals with CD [ 12]. Another link between these two diseases is represented by the ability of gliadin to act as a lectin and to form immunocomplexes with IgA1N (oligosaccharide-containing IgA). Coppo et al. were able to induce experimental IgAN in mice immunized with gliadin [ 3]. The same authors showed a positive effect of a gluten free diet on proteinuria and on progression of renal failure in patients with IgAN. Berthelot et al. showed how activation of transglutaminase 2 is crucial for the deposition of immune-complexes in the mesangium of patients with IgAN [ 13]. Lechner et al. showed that the removal of IgA deposits by a proteases led to a decrease of TG2 staining thus confirming the presence of the enzyme in mesangial immunocomplexes [ 14].
In several case reports, an improvement of IgAN is described following a gluten free diet [ 1517]. All these cases are characterized by the presence of a biopsy proven CD and in no caseis a contemporary immune activation in intestine and kidney reported before the development of duodenal atrophy.
Our finding can explain how CD and IgAN are related. As we found deposits of IgA anti-tissue transglutaminase both in the duodenum and glomerular mesangium we can argue that an autoimmune activation, triggered by gluten in intestinal mucosa and involving tissue transglutaminase, mayoccur in extraintestinal target sites. This kind of association has been demonstrated in other diseases such as GA and in DH, where the role of gluten is well recognized, and a gluten free diet is beneficial [ 5, 6]. Duodenal atrophy can be absentalso in these diseases, as auto-antibodies production is directed against specific transglutaminase isotypes represented, in dermis, by isotype 3, and in myelin by isotype 6, in DH and GA, respectively, In particular, in GA a contemporary presence of anti-tTG2 deposits was found in jejunal mucosa and within the muscular layer of brain vessels and brain parenchyma particularly of the cerebellum, regardless of the presence of duodenal atrophy or positive celiac serology. In our case the strength of pathogeneticassociation between CD and IgAN depends on the diagnostic power of the technique we adopted to detect a gluten dependent immune activation. Duodenal deposits oftTG2 are very sensitive and specific for diagnosis of celiac disease, even in the absence of duodenal atrophy and positive celiac serology [ 18]. Moreover, Salmi et al. [ 10] showed how mucosal anti-tTG2 deposits strongly predict forthcoming duodenal atrophy.
Actually, after one year, the patient developed a duodenal pathology, thus confirming that intestinal deposits of anti-tTG2 were the initial manifestation of a gluten driven inflammation. As transglutaminase 2 is the most represented isoform in the mesangium, we suggest that mesangial deposition of anti-tTG-2 may play a determinant role in pathogenesis of the disease even in the absence of other signs suggesting celiac disease.
Our findings suggest an immune-mediated gluten-induced pathogenetic link between CD and IgAN even in the absence of villous atrophy and serum celiac autoantibodies. Searching for mesangial deposits of anti-tTG2 in a large series of new cases of IgAN will allow to define how many cases are caused by this autoimmune mechanism and if a gluten free diet can really improve renal outcome of these patients.


The authors thank Trays Macdonnell for the English language revision of the article.

Availability of data and materials

Raw data are available upon request to the corresponding author.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent for publication of clinical details and clinical images was obtained from the patient.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

BMC Gastroenterology 1/2018 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin